Inhibitory effect of carboplatin in combination with bevacizumab on human retinoblastoma in an in vitro and in vivo model

Zhang,Qi; Cheng,Yong; Huang,Lvzhen; Bai,Yujing; Liang,Jianhong; Li,Xiaoxin

doi:10.3892/ol.2017.6827

Inhibitory effect of carboplatin in combination with bevacizumab on human retinoblastoma in an in vitro and in vivo model

Authors:
- Qi Zhang
- Yong Cheng
- Lvzhen Huang
- Yujing Bai
- Jianhong Liang
- Xiaoxin Li
View Affiliations

Affiliations: Department of Ophthalmology, The People's Hospital, Peking University, Beijing 100044, P.R. China
Published online on: August 25, 2017 https://doi.org/10.3892/ol.2017.6827
Pages: 5326-5332
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Retinoblastoma is the most common type of malignant intraocular tumor in children, and angiogenesis is required for tumor growth and expansion. The present study investigated whether use of the vascular endothelial growth factor inhibitor antibody bevacizumab can increase the inhibitory effect of carboplatin on human retinoblastoma Y79 cells. This was investigated using in vitro and in vivo models. Cell proliferation was assayed using a Cell Counting Kit‑8 assay, which tested different concentrations of carboplatin in combination with bevacizumab. Cell apoptosis and cell cycle were analyzed using flow cytometry. Protein levels of related signaling pathway molecules were determined by western blotting. The present study used an intravitreal retinoblastoma mouse model for the in vivo study (n=40). Tumors were analyzed histologically. The present study revealed that combining bevacizumab and carboplatin in an in vitro culture of Y79 cells led to a higher inhibition of cellular proliferation than carboplatin alone (P<0.05). The drug combination caused increased apoptosis, and a greater inhibition of the phosphoinositide 3‑kinase (PI3K)/protein kinase B (Akt) and mitogen activated protein kinase (MAPK)/extracellular signal‑regulated kinase (ERK) pathways. This combination also effectively inhibited tumor growth in vivo (P<0.05). These results demonstrate that a combination of carboplatin and bevacizumab results in a greater antitumor effect in advanced human retinoblastoma in vitro and in vivo by inhibiting the PI3K/Akt and MAPK/ERK pathways.

View Figures

View References

1	Broaddus E, Topham A and Singh AD: Incidence of retinoblastoma in the USA: 1975–2004. Br J Ophthalmol. 93:21–23. 2009. View Article : Google Scholar : PubMed/NCBI
2	Kivelä T: The epidemiological challenge of the most frequent eye cancer: Retinoblastoma, an issue of birth and death. Br J Ophthalmol. 93:1129–1131. 2009. View Article : Google Scholar : PubMed/NCBI
3	Seregard S, Lundell G, Svedberg H and Kivelä T: Incidence of retinoblastoma from 1958 to 1998 in Northern Europe: Advantages of birth cohort analysis. Ophthalmology. 111:1228–1232. 2004. View Article : Google Scholar : PubMed/NCBI
4	Chintagumpala M, Chevez-Barrios P, Paysse EA, Plon SE and Hurwitz R: Retinoblastoma: Review of current management. Oncologist. 12:1237–1246. 2007. View Article : Google Scholar : PubMed/NCBI
5	Shields CL, Mashayekhi A, Au AK, Czyz C, Leahey A, Meadows AT and Shields JA: The International classification of retinoblastoma predicts chemoreduction success. Ophthalmology. 113:2276–2280. 2006. View Article : Google Scholar : PubMed/NCBI
6	Balmer A, Zografos L and Munier F: Diagnosis and current management of retinoblastoma. Oncogene. 25:5341–5349. 2006. View Article : Google Scholar : PubMed/NCBI
7	Wheate NJ, Walker S, Craig GE and Oun R: The status of platinum anticancer drugs in the clinic and in clinical trials. Dalton Trans. 39:8113–8127. 2010. View Article : Google Scholar : PubMed/NCBI
8	Shields CL, Kaliki S, Rojanaporn D, Al-Dahmash S, Bianciotto CG and Shields JA: Intravenous and intra-arterial chemotherapy for retinoblastoma: What have we learned? Curr Opin Ophthalmol. 23:202–209. 2012. View Article : Google Scholar : PubMed/NCBI
9	Harbour JW, Murray TG, Hamasaki D, Cicciarelli N, Hernández E, Smith B, Windle J and O'Brien JM: Local carboplatin therapy in transgenic murine retinoblastoma. Invest Ophthalmol Vis Sci. 37:1892–1898. 1996.PubMed/NCBI
10	Murray TG, Roth DB, O'Brien JM, Feuer W, Cicciarelli N, Markoe AM, Hernández E, Smith BJ and Windle JJ: Local carboplatin and radiation therapy in the treatment of murine transgenic retinoblastoma. Arch Ophthalmol. 114:1385–1389. 1996. View Article : Google Scholar : PubMed/NCBI
11	Gombos DS, Kelly A, Coen PG, Kingston JE and Hungerford JL: Retinoblastoma treated with primary chemotherapy alone: The significance of tumour size, location, and age. Br J Ophthalmol. 86:80–83. 2002. View Article : Google Scholar : PubMed/NCBI
12	Folkman J: Tumor angiogenesis: Therapeutic implications. N Engl J Med. 285:1182–1186. 1971. View Article : Google Scholar : PubMed/NCBI
13	Shibuya M: VEGF-VEGFR signals in health and disease. Biomol Ther (Seoul). 22:1–9. 2014. View Article : Google Scholar : PubMed/NCBI
14	Missotten GS, Schlingemann RO and Jager MJ: Angiogenesis and vascular endothelial growth factors in intraocular tumors. Dev Ophthalmol. 46:123–132. 2010. View Article : Google Scholar : PubMed/NCBI
15	Bevacizumab, . Anti-VEGF monoclonal antibody, avastin, rhumab-VEGF. Drugs R D. 3:28–30. 2002.PubMed/NCBI
16	Bai YJ, Huang LZ, Xu XL, Du W, Zhou AY, Yu WZ and Li XX: Polyethylene glycol-modified pigment epithelial-derived factor: New prospects for treatment of retinal neovascularization. J Pharmacol Exp Ther. 342:131–139. 2012. View Article : Google Scholar : PubMed/NCBI
17	Reid TW, Albert DM, Rabson AS, Russell P, Craft J, Chu EW, Tralka TS and Wilcox JL: Characteristics of an established cell line of retinoblastoma. J Natl Cancer Inst. 53:347–360. 1974. View Article : Google Scholar : PubMed/NCBI
18	Areán C, Orellana ME, Abourbih D, Abreu C, Pifano I and Burnier MN Jr: Expression of vascular endothelial growth factor in retinoblastoma. Arch Ophthalmol. 128:223–229. 2010. View Article : Google Scholar : PubMed/NCBI
19	Youssef NS and Said AM: Immunohistochemical expression of CD117 and vascular endothelial growth factor in retinoblastoma: Possible targets of new therapies. Int J Clin Exp Pathol. 7:5725–5737. 2014.PubMed/NCBI
20	Cheng Y, Zheng S, Pan CT, Yuan M, Chang L, Yao Y, Zhao M and Liang J: Analysis of aqueous humor concentrations of cytokines in retinoblastoma. PLoS One. 12:e01773372017. View Article : Google Scholar : PubMed/NCBI
21	Lee SY, Kim DK, Cho JH, Koh JY and Yoon YH: Inhibitory effect of bevacizumab on the angiogenesis and growth of retinoblastoma. Arch Ophthalmol. 126:953–958. 2008. View Article : Google Scholar : PubMed/NCBI
22	Heo JW and Kim JH, Cho CS, Jun HO, Kim DH, Yu YS and Kim JH: Inhibitory activity of bevacizumab to differentiation of retinoblastoma cells. PloS one. 7:e334562012. View Article : Google Scholar : PubMed/NCBI
23	Shilo A, Ben Hur V, Denichenko P, Stein I, Pikarsky E, Rauch J, Kolch W, Zender L and Karni R: Splicing factor hnRNP A2 activates the Ras-MAPK-ERK pathway by controlling A-Raf splicing in hepatocellular carcinoma development. RNA. 20:505–515. 2014. View Article : Google Scholar : PubMed/NCBI
24	Hu Y, Yang H, Lu XQ, Xu F, Li J and Qian J: ARHI suppresses pancreatic cancer by regulating MAPK/ERK 1/2 pathway. Pancreas. 44:342–343. 2015. View Article : Google Scholar : PubMed/NCBI
25	Georgakis GV and Younes A: From Rapa Nui to rapamycin: Targeting PI3K/Akt/mTOR for cancer therapy. Expert Rev Anticancer Ther. 6:131–140. 2006. View Article : Google Scholar : PubMed/NCBI
26	Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS and Ferrara N: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 362:841–844. 1993. View Article : Google Scholar : PubMed/NCBI
27	Mordenti J, Thomsen K, Licko V, Chen H, Meng YG and Ferrara N: Efficacy and concentration-response of murine anti-VEGF monoclonal antibody in tumor-bearing mice and extrapolation to humans. Toxicol Pathol. 27:14–21. 1999. View Article : Google Scholar : PubMed/NCBI